Synact Pharma's Covid-19 disease trials cheaper than expected
Listed company Synact Pharma has moved a study from Europe to Brazil and significantly lowers the expected costs of the trial that tests the company's main candidate as a supplementary treatment for Covid-19 patients.
BY MIKKEL AABENHUS HEMMINGSEN & ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Testing Synact Pharma's pharmaceutical candidate AP1180 as a supplementary treatment for Covid-19 patients will be significantly cheaper than expected, Synact Pharma's Chair Torbjørn Bjerke tells MedWatch after Monday morning.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
